Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Neurosci Res ; 43(4): 317-21, 2002 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12135775

RESUMEN

The neuroprotective effect of carboxyfullerene, a water-soluble derivative of fullerene, on the transient focal ischemia-reperfusion injury was investigated in rat brain. A focal infarction in the cerebral cortex was consistently observed 24 h after a 60-min transient ischemia by occlusion of the right middle cerebral artery and bilateral common carotid arteries. The fluorescent end products of lipid peroxidation were increased in the infarcted cortical area. Furthermore, the GSH level was decreased in the infarcted cortex. Carboxyfullerene was either intravenously (6 mg/kg) or intracerebroventricularly (0.1, 0.3 mg per rat) infused to the chloral hydrate-anesthetized Sprague-Dawley rats 30 min prior to transient ischemia-reperfusion. No protection of cortical infarction was observed after intravenous administration of carboxyfullerene. In contrast, intracerebroventricular infusion of carboxyfullerene not only attenuated cortical infarction but also prevented both the elevated lipid peroxidation and the depleted GSH level induced by transient ischemia-reperfusion. Adverse behavioral changes were simultaneously observed in rats receiving intracerebroventricular infusion of carboxyfullerene (0.3 mg per rat), including writhing accompanied by trunk stretch and even death. Our data suggest that intracerebroventricular infusion of carboxyfullerene may attenuate oxidative injuries by transient ischemia-reperfusion. Nevertheless, undesired side effects may limit the usefulness of carboxyfullerene in biological organisms.


Asunto(s)
Antioxidantes/administración & dosificación , Encéfalo/efectos de los fármacos , Carbono/administración & dosificación , Infarto Cerebral/tratamiento farmacológico , Fármacos Neuroprotectores/administración & dosificación , Animales , Antioxidantes/efectos adversos , Antioxidantes/uso terapéutico , Encéfalo/metabolismo , Carbono/efectos adversos , Carbono/uso terapéutico , Infarto Cerebral/metabolismo , Glutatión/metabolismo , Inyecciones Intravenosas , Inyecciones Intraventriculares , Peróxidos Lipídicos/antagonistas & inhibidores , Masculino , Fármacos Neuroprotectores/efectos adversos , Fármacos Neuroprotectores/uso terapéutico , Ratas , Ratas Sprague-Dawley
2.
Nucl Med Biol ; 29(5): 561-7, 2002 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12088726

RESUMEN

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by a severe loss of the dopaminergic neurons in the substantia nigra pars compacta. In this study, we evaluated pre- and post-synaptic binding sites of the dopamine system in three normal and one parkinsonian monkeys using simultaneous [99mTc]TRODAT-1 and [123I]IBZM imaging. The parkinsonian monkey was induced by injecting 6-hydroxydopamine (6-OHDA) bilaterally into the medial forebrain bundle under MRI guidance. [99mTc]TRODAT-1 (targeting dopamine transporters) and [123I]IBZM (targeting D(2)/D(3) receptors) were administered almost simultaneously and the SPECT images were acquired over 4 h using a dual-headed gamma camera equipped with ultra-high resolution fan-beam collimators. Data were obtained using energy window of 15% centered on 140 keV for 99mTc in conjunction with 10% asymmetric energy window in a lower bound at 159 keV for 123I. Single SPECT studies of [99mTc]TRODAT-1 and [123I]IBZM were also performed. We found a comparable image quality and uptake ratios between single- and dual-isotope studies. There are higher TRODAT-1 uptakes in the control monkeys than the 6-OHDA-lesioned monkey. The uptake of [123I] IBZM showed no significant difference between controls and 6-OHDA-lesioned monkey. Our results suggest that dual isotope imaging using [99mTc]TRODAT-1 and [123I]IBZM may be a useful means in evaluating the changes of both pre- and post-synaptic dopamine system in a primate model of parkinsonism.


Asunto(s)
Benzamidas/farmacocinética , Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Compuestos de Organotecnecio/farmacocinética , Trastornos Parkinsonianos/metabolismo , Pirrolidinas/farmacocinética , Tomografía Computarizada de Emisión de Fotón Único/métodos , Tropanos/farmacocinética , Animales , Dopamina/metabolismo , Macaca , Oxidopamina/administración & dosificación , Trastornos Parkinsonianos/inducido químicamente , Trastornos Parkinsonianos/diagnóstico por imagen , Valor Predictivo de las Pruebas , Radiofármacos/farmacocinética , Valores de Referencia , Sensibilidad y Especificidad , Distribución Tisular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...